DelSiTech develops its own drug products by combining its silica-based drug delivery technology platform with known active substances to produce supergeneric/505(b)(2) products with superior characteristics over the original brand product.
Supergeneric/505(b)(2) drug development provides a low-risk alternative to traditional new chemical entity development in the pharmaceutical industry. With superior characteristics in comparison to the original brand product, supergeneric drug products can generate a significant cash-flow in a much shorter timeframe.
DelSiTech is developing in-house supergeneric/505(b)(2) products to the point at which the preliminary proof-of-concept has been demonstrated in clinical studies. This is followed by global licensing of the product to industry partner(s).